Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
ADMIRE was a prospective, observational cohort study of patients with diabetic macular edema (DME). Efficacy was assessed by change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to months 12, 24 and 36 after treatment with intravitreal aflibercept in treatment-naïve patients and previously treated patients. Safety was evaluated by recording any patients-reported events.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aflibercept | Drug | Intravitreal aflibercept as used in the routice clinical practice |
| Measure | Description | Time Frame |
|---|---|---|
| Change in best-corrected visual acuity | 12 months |
Not provided
Not provided
Inclusion Criteria:
Patients with DM, able to give written informed consent Patients with DME>320 μm, who need treatment
Exclusion Criteria:
Patients with other retinal diseases than DME Intraocular surgery within the last 6 months
Not provided
Not provided
Not provided
Patients with DME treated with intravitreal aflibercept 2.0mg in routice clinical practice.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Athens | Athens | 12462 | Greece |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C533178 | aflibercept |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided